All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Epcoritamab receives approval from EC and Japan Ministry of Health, Labour and Welfare for R/R LBCL
Epcoritimab has received approval from the European Commission and Ministry of Health, Labour and Welfare of Japan for patients with R/R LBCL after...
Impact of bridging therapy on CAR T-cell outcomes in patients with LBCL
Here, we summarize the outcomes of bridging therapy in patients with R/R LBCL undergoing axi-cel or tisa-cel CAR T-cell therapy.